Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Dorr

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Journal of the American Medical Informatics Association : JAMIA|December 1, 2020
Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centersSubha Madhavan, Lisa Bastarache, Jeffrey S Brown, et al.
Journal of the American Medical Informatics Association : JAMIA|February 22, 2023
A multi-site randomized trial of a clinical decision support intervention to improve problem list completenessAdam Wright, Richard Schreiber, David W Bates, et al.
Health Affairs (Project Hope)|April 3, 2018
Primary Care Practices' Abilities And Challenges In Using Electronic Health Record Data For Quality ImprovementDeborah J Cohen, David A Dorr, Kyle Knierim, et al.
JAMA|March 4, 2008
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett, Samuel M Silver, Benjamin Djulbegovic, et al.
Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology|June 2, 2026
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network StudyCindy X Cai, Brian Toy, Benjamin Martin, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Journal of the American Medical Informatics Association : JAMIA|December 1, 2020
Use of electronic health records to support a public health response to the COVID-19 pandemic in the United States: a perspective from 15 academic medical centersSubha Madhavan, Lisa Bastarache, Jeffrey S Brown, et al.
Journal of the American Medical Informatics Association : JAMIA|February 22, 2023
A multi-site randomized trial of a clinical decision support intervention to improve problem list completenessAdam Wright, Richard Schreiber, David W Bates, et al.
Health Affairs (Project Hope)|April 3, 2018
Primary Care Practices' Abilities And Challenges In Using Electronic Health Record Data For Quality ImprovementDeborah J Cohen, David A Dorr, Kyle Knierim, et al.
JAMA|March 4, 2008
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemiaCharles L Bennett, Samuel M Silver, Benjamin Djulbegovic, et al.
Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology|June 2, 2026
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network StudyCindy X Cai, Brian Toy, Benjamin Martin, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 13